162 related articles for article (PubMed ID: 30121630)
1. Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure.
Ferreira JP; Rossignol P; Pizard A; Machu JL; Collier T; Girerd N; Huby AC; Gonzalez A; Diez J; López B; Sattar N; Cleland JG; Sever PS; Zannad F
Heart; 2019 Feb; 105(4):307-314. PubMed ID: 30121630
[TBL] [Abstract][Full Text] [Related]
2. Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial.
Ravassa S; Trippel T; Bach D; Bachran D; González A; López B; Wachter R; Hasenfuss G; Delles C; Dominiczak AF; Pieske B; Díez J; Edelmann F
Eur J Heart Fail; 2018 Sep; 20(9):1290-1299. PubMed ID: 29709099
[TBL] [Abstract][Full Text] [Related]
3. The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial.
Kobayashi M; Girerd N; Ferreira JP; Kevin D; Huttin O; González A; Bozec E; Clark AL; Cosmi F; Cuthbert J; Diez J; Edelmann F; Hazebroek M; Heymans S; Mariottoni B; Pellicori P; Petutschnigg J; Pieske B; Staessen JA; Verdonschot JAJ; Rossignol P; Cleland JGF; Zannad F
Eur J Heart Fail; 2022 Sep; 24(9):1559-1568. PubMed ID: 35703355
[TBL] [Abstract][Full Text] [Related]
4. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome.
Kosmala W; Przewlocka-Kosmala M; Szczepanik-Osadnik H; Mysiak A; O'Moore-Sullivan T; Marwick TH
JACC Cardiovasc Imaging; 2011 Dec; 4(12):1239-49. PubMed ID: 22172779
[TBL] [Abstract][Full Text] [Related]
5. Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin.
López B; González A; Querejeta R; Zubillaga E; Larman M; Díez J
Eur J Heart Fail; 2015 Apr; 17(4):385-92. PubMed ID: 25684565
[TBL] [Abstract][Full Text] [Related]
6. Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study.
Ferreira JP; Duarte K; Montalescot G; Pitt B; de Sa EL; Hamm CW; Flather M; Verheugt F; Shi H; Turgonyi E; Orri M; Rossignol P; Vincent J; Zannad F
Clin Res Cardiol; 2018 Jan; 107(1):49-59. PubMed ID: 28852839
[TBL] [Abstract][Full Text] [Related]
7. High serum level of procollagen type III amino-terminal peptide contributes to the efficacy of spironolactone and angiotensin-converting enzyme inhibitor therapy on left ventricular hypertrophy in essential hypertensive patients.
Sato A; Takane H; Saruta T
Hypertens Res; 2001 Mar; 24(2):99-104. PubMed ID: 11325081
[TBL] [Abstract][Full Text] [Related]
8. Biomarker and imaging responses to spironolactone in subclinical diabetic cardiomyopathy.
Jellis CL; Sacre JW; Wright J; Jenkins C; Haluska B; Jeffriess L; Martin J; Marwick TH
Eur Heart J Cardiovasc Imaging; 2014 Jul; 15(7):776-86. PubMed ID: 24472731
[TBL] [Abstract][Full Text] [Related]
9. The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.
Cleland JGF; Ferreira JP; Mariottoni B; Pellicori P; Cuthbert J; Verdonschot JAJ; Petutschnigg J; Ahmed FZ; Cosmi F; Brunner La Rocca HP; Mamas MA; Clark AL; Edelmann F; Pieske B; Khan J; McDonald K; Rouet P; Staessen JA; Mujaj B; González A; Diez J; Hazebroek M; Heymans S; Latini R; Grojean S; Pizard A; Girerd N; Rossignol P; Collier TJ; Zannad F;
Eur Heart J; 2021 Feb; 42(6):684-696. PubMed ID: 33215209
[TBL] [Abstract][Full Text] [Related]
10. Determinants of anti-fibrotic response to mineralocorticoid receptor antagonist therapy: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure (REMINDER) trials.
Stienen S; Rossignol P; Barros A; Girerd N; Pitt B; Zannad F; Ferreira JP
Clin Res Cardiol; 2020 Feb; 109(2):194-204. PubMed ID: 31250134
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of collagen turnover biomarkers in cardiac resynchronization therapy: A subanalysis of the TRUST CRT randomized trial population.
Sokal A; Lenarczyk R; Kowalski O; Mitrega K; Pluta S; Stabryla-Deska J; Streb W; Urbanik Z; Krzeminski TF; Kalarus Z
Heart Rhythm; 2016 May; 13(5):1088-1095. PubMed ID: 26776557
[TBL] [Abstract][Full Text] [Related]
12. Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure.
Cavallari LH; Momary KM; Groo VL; Viana MA; Camp JR; Stamos TD
Pharmacotherapy; 2007 Jun; 27(6):801-12. PubMed ID: 17542763
[TBL] [Abstract][Full Text] [Related]
13. Serum carboxy terminal propeptide of type I procollagen to amino terminal propeptide of type III procollagen ratio is a better indicator than each single propeptide and 7S domain type IV collagen for progressive fibrogenesis in chronic viral liver diseases.
Lin DY; Chu CM; Sheen IS; Liaw YF
Dig Dis Sci; 1995 Jan; 40(1):21-7. PubMed ID: 7821112
[TBL] [Abstract][Full Text] [Related]
14. Circulating levels of biomarkers of collagen synthesis and ventricular function and dyssynchrony in adolescents and young adults after repair of tetralogy of Fallot.
Lai CT; Chan KW; Wong SJ; Chow PC; Cheung YF
Am Heart J; 2011 Sep; 162(3):467-73. PubMed ID: 21884862
[TBL] [Abstract][Full Text] [Related]
15. Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial.
Pellicori P; Ferreira JP; Mariottoni B; Brunner-La Rocca HP; Ahmed FZ; Verdonschot J; Collier T; Cuthbert JJ; Petutschnigg J; Mujaj B; Girerd N; González A; Clark AL; Cosmi F; Staessen JA; Heymans S; Latini R; Rossignol P; Zannad F; Cleland JGF
Eur J Heart Fail; 2020 Sep; 22(9):1711-1723. PubMed ID: 31950604
[TBL] [Abstract][Full Text] [Related]
16. Predictive Value of Collagen Biomarkers for Heart Failure With and Without Preserved Ejection Fraction: MESA (Multi-Ethnic Study of Atherosclerosis).
Duprez DA; Gross MD; Kizer JR; Ix JH; Hundley WG; Jacobs DR
J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29475876
[TBL] [Abstract][Full Text] [Related]
17. Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade.
Kosmala W; Przewlocka-Kosmala M; Szczepanik-Osadnik H; Mysiak A; Marwick TH
Heart; 2013 Mar; 99(5):320-6. PubMed ID: 23343682
[TBL] [Abstract][Full Text] [Related]
18. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients.
MacFadyen RJ; Barr CS; Struthers AD
Cardiovasc Res; 1997 Jul; 35(1):30-4. PubMed ID: 9302344
[TBL] [Abstract][Full Text] [Related]
19. Relations between markers of cardiac remodelling and left ventricular collagen in an isoproterenol-induced heart damage model.
Adamcova M; Baka T; Dolezelova E; Aziriova S; Krajcirovicova K; Karesova I; Stanko P; Repova K; Simko F
J Physiol Pharmacol; 2019 Feb; 70(1):. PubMed ID: 31019126
[TBL] [Abstract][Full Text] [Related]
20. Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trials.
Ferreira JP; Cleland JG; Girerd N; Rossignol P; Pellicori P; Cosmi F; Mariottoni B; González A; Diez J; Solomon SD; Claggett B; Pfeffer MA; Pitt B; Petutschnigg J; Pieske B; Edelmann F; Zannad F
Int J Cardiol; 2023 Apr; 377():86-88. PubMed ID: 36738846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]